Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 10/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ARHGDIA | P52565 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25880716 | 0.78 | KCNH2 (0.39) | KCNH2OPRK1OPRM1OPRD1CHRM2 | |
| SCHEMBL30833233 | 0.77 | KCNH2 (0.56) | KCNH2OPRK1OPRM1OPRD1 | |
| SCHEMBL30833216 | 0.71 | KCNH2 (0.58) | KCNH2OPRK1OPRM1OPRD1 | |
| SCHEMBL13993541 | 0.69 | CHRM2 (0.62) | KCNH2OPRK1OPRM1OPRD1ALDH1A1 | |
| SCHEMBL694189 | 0.69 | CHRM2 (0.62) | KCNH2OPRK1OPRM1OPRD1ALDH1A1 | |
| SCHEMBL16766562 | 0.69 | CHRM2 (0.62) | KCNH2OPRK1OPRM1OPRD1ALDH1A1 | |
| SCHEMBL16766586 | 0.69 | CHRM2 (0.62) | KCNH2OPRK1OPRM1OPRD1ALDH1A1 | |
| SCHEMBL20483452 | 0.68 | CHRM2 (0.64) | KCNH2OPRK1OPRM1ALDH1A1CHRM2 | |
| SCHEMBL3971648 | 0.68 | CHRM2 (0.56) | KCNH2OPRK1OPRM1OPRD1ALDH1A1 | |
| SCHEMBL12794646 | 0.68 | CHRM2 (0.56) | KCNH2OPRK1OPRM1OPRD1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227474-A1 | COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230227474-A1 | COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227474-A1 | COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING | RBM17, SF3B1, SF3B5 | KCNH2 4599/4885OPRK1 3864/4885OPRM1 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.